MX2017009272A - Anticuerpos que penetran en células. - Google Patents

Anticuerpos que penetran en células.

Info

Publication number
MX2017009272A
MX2017009272A MX2017009272A MX2017009272A MX2017009272A MX 2017009272 A MX2017009272 A MX 2017009272A MX 2017009272 A MX2017009272 A MX 2017009272A MX 2017009272 A MX2017009272 A MX 2017009272A MX 2017009272 A MX2017009272 A MX 2017009272A
Authority
MX
Mexico
Prior art keywords
cell penetrating
phosphorothioate
conjugates
nucleic acid
polymer backbone
Prior art date
Application number
MX2017009272A
Other languages
English (en)
Inventor
Herrmann Andreas
Yu Hua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of MX2017009272A publication Critical patent/MX2017009272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en el presente documento conjugados que penetran en células. Los conjugados incluyen una proteína que no penetra en células unida a un ácido nucleico de fosforotioato o polímero de cadena principal de fosforotioato mediante un enlazador no covalente que incluye un dominio de unión a biotina y un dominio de biotina, en el que el ácido nucleico de fosforotioato o polímero de cadena principal de fosforotioato potencia la administración intracelular de la proteína que no penetra en células. También se proporcionan composiciones y kits que comprenden los conjugados.
MX2017009272A 2015-01-16 2016-01-15 Anticuerpos que penetran en células. MX2017009272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104653P 2015-01-16 2015-01-16
PCT/US2016/013668 WO2016115500A1 (en) 2015-01-16 2016-01-15 Cell penetrating antibodies

Publications (1)

Publication Number Publication Date
MX2017009272A true MX2017009272A (es) 2018-04-11

Family

ID=56406478

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009272A MX2017009272A (es) 2015-01-16 2016-01-15 Anticuerpos que penetran en células.
MX2021011584A MX2021011584A (es) 2015-01-16 2017-07-14 Anticuerpos que penetran en celulas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011584A MX2021011584A (es) 2015-01-16 2017-07-14 Anticuerpos que penetran en celulas.

Country Status (18)

Country Link
US (1) US11730789B2 (es)
EP (2) EP3244910B1 (es)
JP (2) JP7260248B2 (es)
KR (1) KR20170098957A (es)
CN (2) CN107427550B (es)
AR (1) AR103428A1 (es)
AU (2) AU2016206475B2 (es)
BR (1) BR112017015203A2 (es)
CA (1) CA2972986A1 (es)
EA (1) EA201791610A1 (es)
IL (1) IL253403A0 (es)
MX (2) MX2017009272A (es)
PH (1) PH12017501271A1 (es)
SG (1) SG11201705413WA (es)
TW (1) TW201632207A (es)
UY (1) UY36519A (es)
WO (1) WO2016115500A1 (es)
ZA (2) ZA201705120B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017009272A (es) * 2015-01-16 2018-04-11 Anticuerpos que penetran en células.
AU2016270823B2 (en) 2015-06-01 2020-09-03 California Institute Of Technology Compositions and methods for screening T cells with antigens for specific populations
EP3331543A4 (en) 2015-08-06 2019-03-20 City of Hope CONJUGATES OF CELL PENETRATION FORMED OF PROTEIN AND ANTIBODIES AND METHODS OF USE
WO2019014648A1 (en) 2017-07-13 2019-01-17 City Of Hope PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE
CN111699002B (zh) * 2017-12-22 2024-06-28 罗菲佰欧株式会社 抗stat3双特异性抗体及包含其的药学组合物
KR102075724B1 (ko) 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
WO2021226107A1 (en) * 2020-05-05 2021-11-11 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
US20230321250A1 (en) * 2020-07-08 2023-10-12 Octagon Therapeutics, Inc. Cancer cell modulators
KR20220055412A (ko) 2020-10-26 2022-05-03 한국원자력의학원 로자탄을 유효성분으로 포함하는 항암제의 종양 침투력 증진용 조성물 및 이의 용도
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
SG167667A1 (en) * 2002-07-03 2011-01-28 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
MX2008002743A (es) * 2005-08-31 2008-03-26 Oncolytics Biotech Inc Potenciacion in vivo del reconocimiento de neoplasmas por el sistema inmunitario posterior a viroterapia oncolitica o vector para terapia genica.
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20100239504A1 (en) 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
WO2010006237A2 (en) 2008-07-11 2010-01-14 Alnylam Pharmaceuticals, Inc. Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents
CA2731779A1 (en) * 2008-07-24 2010-01-28 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
CN105658230B (zh) * 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
MX2017009272A (es) * 2015-01-16 2018-04-11 Anticuerpos que penetran en células.
CN107980001B (zh) * 2015-07-02 2021-12-17 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
EP3331573A4 (en) 2015-08-06 2019-02-27 City of Hope THERAPEUTIC CONJUGATES OF CELL INTERNALIZATION

Also Published As

Publication number Publication date
KR20170098957A (ko) 2017-08-30
IL253403A0 (en) 2017-09-28
EP3244910B1 (en) 2020-09-16
CN107427550B (zh) 2021-10-08
PH12017501271A1 (en) 2018-02-05
JP7260248B2 (ja) 2023-04-18
JP2018505870A (ja) 2018-03-01
JP2021152022A (ja) 2021-09-30
CN113797349A (zh) 2021-12-17
ZA201705120B (en) 2022-02-23
CN107427550A (zh) 2017-12-01
TW201632207A (zh) 2016-09-16
UY36519A (es) 2016-08-31
US11730789B2 (en) 2023-08-22
EP3244910A4 (en) 2018-08-08
EA201791610A1 (ru) 2017-12-29
SG11201705413WA (en) 2017-08-30
ZA202105220B (en) 2023-01-25
CA2972986A1 (en) 2016-07-21
MX2021011584A (es) 2021-10-13
EP3795168A1 (en) 2021-03-24
WO2016115500A1 (en) 2016-07-21
EP3244910A1 (en) 2017-11-22
US20180008667A1 (en) 2018-01-11
AU2022200592A1 (en) 2022-02-24
AR103428A1 (es) 2017-05-10
AU2016206475B2 (en) 2021-11-04
BR112017015203A2 (pt) 2018-03-13
AU2016206475A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
MX2021011584A (es) Anticuerpos que penetran en celulas.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
CY1121911T1 (el) Cd47 αντισωματα και μεθοδοι χρησης αυτων
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX2019007020A (es) Anticuerpos il-11.
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
WO2015151078A3 (en) Hydrophilic linkers for conjugation
MX354450B (es) Anticuerpos anti proteína accesoria del receptor de interleucina-1 y su uso para tratamiento en humanos.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201590173A1 (ru) Иммуноконъюгаты, содержащие антитела к cd22
BR112013003825A2 (pt) conjugados, partículas, composições e métodos relacionados
NZ703581A (en) Anti-cd70 antibody drug conjugates
EA201891460A1 (ru) Композиция дендритных клеток
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
ZA202001040B (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
CY1123421T1 (el) Ενεργειακα ποτα και αλλα θρεπτικα βοηθηματα που προερχονται απο αλκοολουχα ποτα με βαση την αγαυη
CY1123949T1 (el) Μεθοδοι και συνθεσεις για την αναστολη της παθολογιας που σχετιζεται με πολυομαϊο
CY1119959T1 (el) ΔΕΝΔΡΙΤΙΚΑ ΚΥΤΤΑΡΑ ΥΠΟΒΛΗΘΕΝΤΑ ΣΕ ΧΕΙΡΙΣΜΟ ΣΤΗΝ ΠΟΡΕΙΑ ΣΗΜΑΤΟΔΟΤΗΣΗΣ NFkB